MX2016003199A - Compuestos de azapiridona y usos de los mismos. - Google Patents
Compuestos de azapiridona y usos de los mismos.Info
- Publication number
- MX2016003199A MX2016003199A MX2016003199A MX2016003199A MX2016003199A MX 2016003199 A MX2016003199 A MX 2016003199A MX 2016003199 A MX2016003199 A MX 2016003199A MX 2016003199 A MX2016003199 A MX 2016003199A MX 2016003199 A MX2016003199 A MX 2016003199A
- Authority
- MX
- Mexico
- Prior art keywords
- aza
- pyridone compounds
- infection
- disclosed
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Se describen en la presente compuestos de azapiridona, composiciones farmacéuticas que incluyen uno o más compuestos de azapiridona, y métodos de síntesis de los mismos. También se describen en la presente métodos para mejorar y/o tratar una enfermedad y/o una condición, incluyendo una infección por ortomixovirus, con un compuesto de azapiridona. Los ejemplos de una infección viral por ortomixovirus incluyen infección por influenza.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877151P | 2013-09-12 | 2013-09-12 | |
US201462011784P | 2014-06-13 | 2014-06-13 | |
US201462031673P | 2014-07-31 | 2014-07-31 | |
PCT/US2014/055012 WO2015038655A1 (en) | 2013-09-12 | 2014-09-10 | Aza-pyridone compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016003199A true MX2016003199A (es) | 2016-06-02 |
Family
ID=52626171
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016003199A MX2016003199A (es) | 2013-09-12 | 2014-09-10 | Compuestos de azapiridona y usos de los mismos. |
MX2020012132A MX2020012132A (es) | 2013-09-12 | 2016-03-10 | Compuestos de azapiridona y usos de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012132A MX2020012132A (es) | 2013-09-12 | 2016-03-10 | Compuestos de azapiridona y usos de los mismos. |
Country Status (19)
Country | Link |
---|---|
US (5) | US9328119B2 (es) |
EP (2) | EP3030566B1 (es) |
JP (1) | JP6448647B2 (es) |
KR (2) | KR102468319B1 (es) |
CN (1) | CN105764904B (es) |
AU (2) | AU2014318832B2 (es) |
BR (1) | BR112016005270B1 (es) |
CA (1) | CA2923075C (es) |
CL (1) | CL2016000539A1 (es) |
EA (1) | EA037949B1 (es) |
ES (1) | ES2821394T3 (es) |
HK (1) | HK1225715A1 (es) |
IL (2) | IL244432B (es) |
MX (2) | MX2016003199A (es) |
PE (1) | PE20160661A1 (es) |
PH (1) | PH12016500486A1 (es) |
TW (1) | TWI652269B (es) |
UA (1) | UA121199C2 (es) |
WO (1) | WO2015038655A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20120508A1 (es) | 2009-06-17 | 2012-05-09 | Vertex Pharma | Inhibidores de la replicacion de los virus de la gripe |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
EP3421482A1 (en) | 2012-12-21 | 2019-01-02 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CA2923075C (en) | 2013-09-12 | 2022-07-26 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
MX370085B (es) | 2013-09-12 | 2019-11-29 | Janssen Biopharma Inc | Compuestos de piridazinona y usos de los mismos. |
EA036776B1 (ru) * | 2015-03-11 | 2020-12-21 | Янссен Байофарма, Инк. | Соединения азапиридона и способы их применения |
FI3290424T3 (fi) | 2015-04-28 | 2024-02-26 | Shionogi & Co | Substituoituneita polysyklisiä pyridonijohdannaisia ja niiden aihiolääkkeitä |
KR102409779B1 (ko) | 2015-04-28 | 2022-06-16 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그 |
JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
US9988390B2 (en) | 2015-10-30 | 2018-06-05 | F. Hoffmann-La Roche Ag | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
RU2745071C2 (ru) | 2015-12-15 | 2021-03-18 | Сионоги Энд Ко., Лтд. | Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа |
US10858366B2 (en) | 2016-03-08 | 2020-12-08 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
WO2017156407A1 (en) * | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017223231A1 (en) | 2016-06-21 | 2017-12-28 | Alios Biopharma, Inc. | (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza |
CN110494141A (zh) | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物 |
JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
CA3088926A1 (en) * | 2018-01-17 | 2019-07-25 | Jiangxi Caishi Pharmaceutical Technology Co., Ltd. | Pyridone derivative, composition and use as antiviral drug thereof |
MX2020008959A (es) * | 2018-02-28 | 2020-10-05 | Novartis Ag | Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza. |
ES2937837T3 (es) * | 2018-09-10 | 2023-03-31 | Cocrystal Pharma Inc | Inhibidores de piridopirazina y piridotriazina de la replicación del virus de la gripe |
US20230290957A1 (en) | 2020-12-14 | 2023-09-14 | The School Corporation Kansai University | Electrode for electrochemical device and non-aqueous electrolyte secondary battery |
CN117126044B (zh) * | 2023-04-12 | 2024-01-26 | 延边大学 | 一种微波辅助的甲基酮类化合物的合成方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
CN100357284C (zh) * | 2003-09-11 | 2007-12-26 | 浙江海正药业股份有限公司 | 抗流感病毒化合物及其制备方法和用途 |
WO2005087766A1 (en) * | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
WO2005099699A1 (en) | 2004-04-07 | 2005-10-27 | Sepracor Inc. | Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension |
WO2006028963A2 (en) | 2004-09-03 | 2006-03-16 | Celgene Corporation | Substituted heterocyclic compounds and uses thereof |
ZA200805191B (en) * | 2005-11-28 | 2009-08-26 | Hk Omega Biopharma Ltd | Materials and methods for treating viral infections with a cysteamine compound |
AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
FR2909090B1 (fr) | 2006-11-23 | 2009-01-09 | Sanofi Aventis Sa | Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique. |
CN101880280B (zh) | 2006-12-22 | 2014-07-16 | 中国科学院上海有机化学研究所 | 双环嘧啶酮以及其应用 |
FR2921505B1 (fr) | 2007-09-25 | 2014-01-31 | Alstom Transport Sa | Dispositif de communication radioelectrique |
JP2009096991A (ja) | 2007-09-27 | 2009-05-07 | Fujifilm Corp | 硬化性組成物、画像形成材料及び平版印刷版原版 |
WO2009053799A1 (en) | 2007-10-24 | 2009-04-30 | Glenmark Pharmaceuticals, S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
EP2364314B1 (en) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
EP2375899B1 (en) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
CA2750708A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators |
TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
WO2010110231A1 (ja) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された3-ヒドロキシ-4-ピリドン誘導体 |
TWI518084B (zh) * | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
WO2010138419A2 (en) * | 2009-05-23 | 2010-12-02 | Obio Pharmaceutical (H.K.) Ltd. | Materials and methods for treating viral infections |
LT2444400T (lt) * | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
WO2011084371A1 (en) | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
KR20120130185A (ko) * | 2010-02-26 | 2012-11-29 | 니뽄 다바코 산교 가부시키가이샤 | 1,3,4,8―테트라히드로―2H―피리도[1,2―a]피라진 유도체 및 그의 HIV 인테그라제 저해제로서의 이용 |
EP3235818A3 (en) | 2010-04-01 | 2018-03-14 | Critical Outcome Technologies, Inc. | Compounds for the treatment of hiv |
US20130116231A1 (en) | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
HUE039859T2 (hu) * | 2010-09-24 | 2019-02-28 | Shionogi & Co | Helyettesített policiklusos karbamoil-piridon-származék prodrug |
KR20140071454A (ko) | 2011-09-30 | 2014-06-11 | 키네타, 인크. | 항바이러스 화합물 |
CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
CA2923075C (en) | 2013-09-12 | 2022-07-26 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
MX370085B (es) | 2013-09-12 | 2019-11-29 | Janssen Biopharma Inc | Compuestos de piridazinona y usos de los mismos. |
CR20160557A (es) | 2014-05-29 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 |
EA036776B1 (ru) * | 2015-03-11 | 2020-12-21 | Янссен Байофарма, Инк. | Соединения азапиридона и способы их применения |
WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
WO2017223231A1 (en) | 2016-06-21 | 2017-12-28 | Alios Biopharma, Inc. | (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza |
JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
-
2014
- 2014-09-10 CA CA2923075A patent/CA2923075C/en active Active
- 2014-09-10 BR BR112016005270-6A patent/BR112016005270B1/pt active IP Right Grant
- 2014-09-10 KR KR1020217035836A patent/KR102468319B1/ko active IP Right Grant
- 2014-09-10 PE PE2016000369A patent/PE20160661A1/es unknown
- 2014-09-10 US US14/482,886 patent/US9328119B2/en active Active
- 2014-09-10 KR KR1020167009194A patent/KR102323515B1/ko active IP Right Grant
- 2014-09-10 EP EP14844961.4A patent/EP3030566B1/en active Active
- 2014-09-10 UA UAA201602294A patent/UA121199C2/uk unknown
- 2014-09-10 ES ES14844961T patent/ES2821394T3/es active Active
- 2014-09-10 WO PCT/US2014/055012 patent/WO2015038655A1/en active Application Filing
- 2014-09-10 EP EP20184298.6A patent/EP3778603A1/en active Pending
- 2014-09-10 AU AU2014318832A patent/AU2014318832B2/en active Active
- 2014-09-10 CN CN201480061771.XA patent/CN105764904B/zh active Active
- 2014-09-10 JP JP2016542073A patent/JP6448647B2/ja active Active
- 2014-09-10 MX MX2016003199A patent/MX2016003199A/es active IP Right Grant
- 2014-09-10 EA EA201690372A patent/EA037949B1/ru unknown
- 2014-09-12 TW TW103131647A patent/TWI652269B/zh active
-
2016
- 2016-03-03 IL IL244432A patent/IL244432B/en active IP Right Grant
- 2016-03-09 CL CL2016000539A patent/CL2016000539A1/es unknown
- 2016-03-10 MX MX2020012132A patent/MX2020012132A/es unknown
- 2016-03-11 PH PH12016500486A patent/PH12016500486A1/en unknown
- 2016-04-28 US US15/141,387 patent/US10251882B2/en active Active
- 2016-12-06 HK HK16113897A patent/HK1225715A1/zh unknown
-
2019
- 2019-02-28 AU AU2019201403A patent/AU2019201403B2/en active Active
- 2019-03-01 US US16/290,690 patent/US10702523B2/en active Active
- 2019-08-09 US US16/537,396 patent/US10980805B2/en active Active
-
2020
- 2020-04-30 IL IL274355A patent/IL274355B/en active IP Right Grant
-
2021
- 2021-02-25 US US17/185,750 patent/US20210186969A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500486A1 (en) | Aza-pyridone compounds and uses thereof | |
PH12016500492B1 (en) | Pyridazinone compounds and uses thereof | |
MX2017011655A (es) | Compuestos de aza-piridona y usos de estos. | |
MX2021002168A (es) | Compuestos antivirales. | |
MA40404A (fr) | Polythérapie pour traiter un paramyxovirus | |
EA201790630A1 (ru) | Способы получения рибозидов | |
MX2022015755A (es) | Profarmacos de hormona paratiroidea (pth). | |
GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
MX2015016755A (es) | Reagrupamiento del virus de influenza. | |
WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
MX2017012553A (es) | Compuestos espirociclicos. | |
NZ742805A (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
IN2013MU01985A (es) | ||
GEP20186908B (en) | P-substituted asymmetric ureas and medical uses thereof | |
MX2015009330A (es) | Reordenamiento del virus de influenza. | |
PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
PH12016502592A1 (en) | 3'-substituted-abscisic acid derivatives | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
MX2016016612A (es) | Formulaciones estables de undecanoato de testosterona. | |
IN2014KN02584A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: ABBVIE STEMCENTRX LLC |
|
FG | Grant or registration |